Compare MNKD & KODK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MNKD | KODK |
|---|---|---|
| Founded | 1991 | 1880 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 982.9M |
| IPO Year | 2004 | 1994 |
| Metric | MNKD | KODK |
|---|---|---|
| Price | $3.76 | $8.94 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $8.69 | N/A |
| AVG Volume (30 Days) | ★ 3.1M | 789.3K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $348,966,000.00 | ★ $4,114,000,000.00 |
| Revenue This Year | $35.81 | N/A |
| Revenue Next Year | $11.89 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 22.23 | N/A |
| 52 Week Low | $2.23 | $5.78 |
| 52 Week High | $6.51 | $14.87 |
| Indicator | MNKD | KODK |
|---|---|---|
| Relative Strength Index (RSI) | 41.68 | 41.97 |
| Support Level | $3.30 | $8.71 |
| Resistance Level | $4.23 | $9.13 |
| Average True Range (ATR) | 0.17 | 0.31 |
| MACD | -0.03 | -0.08 |
| Stochastic Oscillator | 0.00 | 17.63 |
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
Eastman Kodak Co is a United States-based company. It operates through several business segments; Print, Brand, and Advanced Materials and Chemicals. The Print segment which derives the majority of revenue includes products like digital offset plate offerings and computer-to-plate imaging solutions, high-quality digital printing solutions using electrically charged toner-based technology, production press systems, consumables, inkjet components, software and services. Geographically, the company generates revenue from the United States, Canada, Europe, Middle East and Africa, Asia Pacific, and Latin America.